Accueil>>Signaling Pathways>> DNA Damage/DNA Repair>> Checkpoint Kinase (Chk)>>Chk1-IN-5

Chk1-IN-5

Catalog No.GC60698

Chk1-IN-5 est un puissant inhibiteur de la kinase de point de contrÔle 1 (Chk1). Chk1-IN-5 inhibe la phosphorylation de Chk1 et inhibe la croissance tumorale dans le modèle de xénogreffe du cancer du cÔlon.

Products are for research use only. Not for human use. We do not sell to patients.

Chk1-IN-5 Chemical Structure

Cas No.: 2120398-39-0

Taille Prix Stock Qté
100mg
185,00 $US
En stock
250mg
334,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Chk1-IN-5 is a potent checkpoint kinase 1 (Chk1) inhibitor. Chk1-IN-5 inhibits Chk1 phosphorylation and inhibits tumor growth in colon cancer xenograft model[1].

Chk1-IN-5 (compound 3; 0.4, 1.2, 3.7, 11.1, 33.3, 100 nM) inhibits Chk1 phosphorylation in the HT-29 colon cells[1].

Chk1-IN-5 (compound 3; 40 mg/kg; IV; twice a week for 21 days) inhibits tumor growth in Baib/c nude mice with HT-29 colon cancer cells[1].Chk1-IN-5 (10 mg/kg; via tail vein intravenous injection) displays a longer half-life (T1/2=3.8 hours) and higher exposure (CL=2.3 L/hr•kg; Vss=6.4 L/kg; AUC=4531 ng/ml•h)[1]. Animal Model: Baib/c nude mice with HT-29 colon cancer cells[1]

[1]. Xiong Cai, et al. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications. WO2017132928A1.

Avis

Review for Chk1-IN-5

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Chk1-IN-5

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.